beta

ANAB

AnaptysBio Inc.

Anab

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-08-2018 08-07-2018 05-08-2018 03-05-2018 11-07-2017 08-10-2017 05-11-2017
Actual EPS -0.66 -0.57 -0.63 -0.3 -0.45 -0.13 -0.75
Consensus EPS -0.69 -0.71 -0.44 -0.41 -0.46 -0.44 -0.25
Estimated EPS -0.69 -0.71 -0.44 -0.41 -0.46 -0.44 -0.25
Number of Estimates 4 3 4 5 3 3 2
EPS Surprise $0.03 $0.14 -$0.19 $0.11 $0.01 $0.31 -$0.50

Stats

Summary

AnaptysBio Inc is a biotechnology company. The Company is engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.

Market Cap: 2.67 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.anaptysbio.com

Shares Outstanding: 23.5 Million

Float: 23.1 Million

Dividend: 0.0 (0.0%)

Beta: 3.792185

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 1.49 Million

Ethical Flags

Animal testing

Longest drawdown: 218 trading days

From: 2018-03-02 To: 2018-12-14

Lowest Point:

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-26 10:05:28:000

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2018. Please visit our Tracking Ole Andreas Halvorsen… read more...

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-26 10:05:28:000

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2018. Please visit our Tracking Ole Andreas Halvorsen… read more...

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2018 Update

via: SeekingAlpha at 2018-11-26 10:05:28:000

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2018. Please visit our Tracking Ole Andreas Halvorsen… read more...

Aimmune up 6% premarket on publication of successful late-stage study of peanut allergy candidate AR101

via: SeekingAlpha at 2018-11-19 06:59:59:000

Aimmune Therapeutics (NASDAQ: AIMT ) is up 6% premarket, albeit on only 800 shares, on the heels of the publication in the New England Journal of Medicine of results from the Phase 3 PALISADE study evaluating AR101 in patients with peanut allergy. More news on: Aimmune Ther… read more...

Aimmune up 6% premarket on publication of successful late-stage study of peanut allergy candidate AR101

via: SeekingAlpha at 2018-11-19 06:59:59:000

Aimmune Therapeutics (NASDAQ: AIMT ) is up 6% premarket, albeit on only 800 shares, on the heels of the publication in the New England Journal of Medicine of results from the Phase 3 PALISADE study evaluating AR101 in patients with peanut allergy. More news on: Aimmune Ther… read more...

Aimmune up 6% premarket on publication of successful late-stage study of peanut allergy candidate AR101

via: SeekingAlpha at 2018-11-19 06:59:59:000

Aimmune Therapeutics (NASDAQ: AIMT ) is up 6% premarket, albeit on only 800 shares, on the heels of the publication in the New England Journal of Medicine of results from the Phase 3 PALISADE study evaluating AR101 in patients with peanut allergy. More news on: Aimmune Ther… read more...

AnaptysBio beats by $0.06, misses on revenue

via: SeekingAlpha at 2018-11-08 16:56:47:000

AnaptysBio (NASDAQ: ANAB ): Q3 GAAP EPS of -$0.66 beats by $0.06 . More news on: AnaptysBio, Earnings news and commentary, Healthcare stocks news, Read more … read more...

AnaptysBio beats by $0.06, misses on revenue

via: SeekingAlpha at 2018-11-08 16:56:47:000

AnaptysBio (NASDAQ: ANAB ): Q3 GAAP EPS of -$0.66 beats by $0.06 . More news on: AnaptysBio, Earnings news and commentary, Healthcare stocks news, Read more … read more...

AnaptysBio beats by $0.06, misses on revenue

via: SeekingAlpha at 2018-11-08 16:56:47:000

AnaptysBio (NASDAQ: ANAB ): Q3 GAAP EPS of -$0.66 beats by $0.06 . More news on: AnaptysBio, Earnings news and commentary, Healthcare stocks news, Read more … read more...

AnaptysBio prices public offering of common stock

via: SeekingAlpha at 2018-09-26 07:26:26:000

AnaptysBio (NASDAQ: ANAB ) prices its public offering of 2.2M shares of common stock at a price of $94.46 per share, for the gross proceeds of ~$207.8M. More news on: AnaptysBio, Healthcare stocks news, Stocks on the move, Read more … read more...

AnaptysBio prices public offering of common stock

via: SeekingAlpha at 2018-09-26 07:26:26:000

AnaptysBio (NASDAQ: ANAB ) prices its public offering of 2.2M shares of common stock at a price of $94.46 per share, for the gross proceeds of ~$207.8M. More news on: AnaptysBio, Healthcare stocks news, Stocks on the move, Read more … read more...

AnaptysBio prices public offering of common stock

via: SeekingAlpha at 2018-09-26 07:26:26:000

AnaptysBio (NASDAQ: ANAB ) prices its public offering of 2.2M shares of common stock at a price of $94.46 per share, for the gross proceeds of ~$207.8M. More news on: AnaptysBio, Healthcare stocks news, Stocks on the move, Read more … read more...

AnaptysBio down 8% premarket on mid-stage etokimab data in eosinophilic asthma

via: SeekingAlpha at 2018-09-24 08:19:24:000

Thinly traded AnaptysBio (NASDAQ: ANAB ) slips 8% premarket on light volume on the heels of its announcement of topline results from a Phase 2a clinical trial evaluating IL-33 inhibitor etokimab in patients with severe eosinophilic asthma. More news on: AnaptysBio, Healthcare stoc… read more...

AnaptysBio down 8% premarket on mid-stage etokimab data in eosinophilic asthma

via: SeekingAlpha at 2018-09-24 08:19:24:000

Thinly traded AnaptysBio (NASDAQ: ANAB ) slips 8% premarket on light volume on the heels of its announcement of topline results from a Phase 2a clinical trial evaluating IL-33 inhibitor etokimab in patients with severe eosinophilic asthma. More news on: AnaptysBio, Healthcare stoc… read more...

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-09-07 07:32:17:000

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-09-07 07:32:17:000

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-09-07 07:32:17:000

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-09-07 07:32:17:000

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update

via: SeekingAlpha at 2018-09-07 07:32:17:000

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...

Intrommune advancing peanut allergy candidate, pre-IND meeting with FDA completed

via: SeekingAlpha at 2018-09-06 11:15:06:000

Privately held Intromune Therapeutics met recently with the FDA to discuss the details of an IND for INT301, an immunotherapy to treat peanut allergy. Once approved, clinical studies may begin. More news on: AnaptysBio, Aimmune Therapeutics, DBV Technologies, Healthcare stocks news, … read more...

AnaptysBio beats by $0.13

via: SeekingAlpha at 2018-08-07 06:49:21:000

AnaptysBio (NASDAQ: ANAB ): Q2 EPS of -$0.57 beats by $0.13 . More news on: AnaptysBio, Earnings news and commentary, Healthcare stocks news, Read more … read more...

AnaptysBio beats by $0.13

via: SeekingAlpha at 2018-08-07 06:49:21:000

AnaptysBio (NASDAQ: ANAB ): Q2 EPS of -$0.57 beats by $0.13 . More news on: AnaptysBio, Earnings news and commentary, Healthcare stocks news, Read more … read more...

AnaptysBio beats by $0.13

via: SeekingAlpha at 2018-08-07 06:49:21:000

AnaptysBio (NASDAQ: ANAB ): Q2 EPS of -$0.57 beats by $0.13 . More news on: AnaptysBio, Earnings news and commentary, Healthcare stocks news, Read more … read more...

AnaptysBio: Elucidating The Prospect Of The Eosinophilic Asthma Franchise

via: SeekingAlpha at 2018-07-26 04:27:48:000

As usual in human affairs, what determines the behavior are incentives for the decision maker, and getting the incentives right is a very, very important lesson. - Charlie Munger AnaptysBio (NASDAQ: ANAB ) is a $1.6B market cap firm that is brewing multiple growth catalys… read more...

AnaptysBio: Elucidating The Prospect Of The Eosinophilic Asthma Franchise

via: SeekingAlpha at 2018-07-26 04:27:48:000

As usual in human affairs, what determines the behavior are incentives for the decision maker, and getting the incentives right is a very, very important lesson. - Charlie Munger AnaptysBio (NASDAQ: ANAB ) is a $1.6B market cap firm that is brewing multiple growth catalys… read more...

AnaptysBio: Elucidating The Prospect Of The Eosinophilic Asthma Franchise

via: SeekingAlpha at 2018-07-26 04:27:48:000

As usual in human affairs, what determines the behavior are incentives for the decision maker, and getting the incentives right is a very, very important lesson. - Charlie Munger AnaptysBio (NASDAQ: ANAB ) is a $1.6B market cap firm that is brewing multiple growth catalys… read more...

AnaptysBio: A Deeper Dive

via: SeekingAlpha at 2018-07-20 12:14:55:000

"Hollywood brides keep the bouquets and throw away the grooms." - Groucho Marx Today we take a look at a new name and outline two possible ways to invest in it after a recent dip in the share price. Company Overview AnaptysBio, Inc. ( ANAB ) is a San Diego based Tier 4 developmen… read more...

AnaptysBio: A Deeper Dive

via: SeekingAlpha at 2018-07-20 12:14:55:000

"Hollywood brides keep the bouquets and throw away the grooms." - Groucho Marx Today we take a look at a new name and outline two possible ways to invest in it after a recent dip in the share price. Company Overview AnaptysBio, Inc. ( ANAB ) is a San Diego based Tier 4 developmen… read more...

AnaptysBio: A Deeper Dive

via: SeekingAlpha at 2018-07-20 12:14:55:000

"Hollywood brides keep the bouquets and throw away the grooms." - Groucho Marx Today we take a look at a new name and outline two possible ways to invest in it after a recent dip in the share price. Company Overview AnaptysBio, Inc. ( ANAB ) is a San Diego based Tier 4 developmen… read more...

AnaptysBio: A Deeper Dive

via: SeekingAlpha at 2018-07-20 12:14:55:000

"Hollywood brides keep the bouquets and throw away the grooms." - Groucho Marx Today we take a look at a new name and outline two possible ways to invest in it after a recent dip in the share price. Company Overview AnaptysBio, Inc. ( ANAB ) is a San Diego based Tier 4 developmen… read more...

AnaptysBio: A Deeper Dive

via: SeekingAlpha at 2018-07-20 12:14:55:000

"Hollywood brides keep the bouquets and throw away the grooms." - Groucho Marx Today we take a look at a new name and outline two possible ways to invest in it after a recent dip in the share price. Company Overview AnaptysBio, Inc. ( ANAB ) is a San Diego based Tier 4 developmen… read more...

Playing The Expectations Game In Biotech

via: SeekingAlpha at 2018-07-17 21:11:17:000

Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th… read more...

Playing The Expectations Game In Biotech

via: SeekingAlpha at 2018-07-17 21:11:17:000

Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th… read more...

Institutional Top Ideas: Cormorant Asset Management

via: SeekingAlpha at 2018-06-16 18:41:14:000

In the last entry of this series we took a look at top ideas from EcoR1 Capital, a hedge fund with high returns and a higher percentage of the portfolio in its top 10 holdings (making it a good one to keep tabs on). The series is down to its last two funds to be reviewed, as usual trying t… read more...

Institutional Top Ideas: Cormorant Asset Management

via: SeekingAlpha at 2018-06-16 18:41:14:000

In the last entry of this series we took a look at top ideas from EcoR1 Capital, a hedge fund with high returns and a higher percentage of the portfolio in its top 10 holdings (making it a good one to keep tabs on). The series is down to its last two funds to be reviewed, as usual trying t… read more...

Institutional Top Ideas: Cormorant Asset Management

via: SeekingAlpha at 2018-06-16 18:41:14:000

In the last entry of this series we took a look at top ideas from EcoR1 Capital, a hedge fund with high returns and a higher percentage of the portfolio in its top 10 holdings (making it a good one to keep tabs on). The series is down to its last two funds to be reviewed, as usual trying t… read more...

Institutional Top Ideas: Cormorant Asset Management

via: SeekingAlpha at 2018-06-16 18:41:14:000

In the last entry of this series we took a look at top ideas from EcoR1 Capital, a hedge fund with high returns and a higher percentage of the portfolio in its top 10 holdings (making it a good one to keep tabs on). The series is down to its last two funds to be reviewed, as usual trying t… read more...

Reader Inquiry: AnaptysBio, Is It Time For Round 2 With This Former ROTY Winner?

via: SeekingAlpha at 2018-05-28 01:56:07:000

Shares of AnaptysBio ( ANAB ) rose by as much as 350% after my initial article prior to pulling back significantly. The stock was also one of the original selections in the ROTY 10 stock model account last year- while my plan had been to hold through phase 2a data in moderate to severe atopi… read more...

Reader Inquiry: AnaptysBio, Is It Time For Round 2 With This Former ROTY Winner?

via: SeekingAlpha at 2018-05-28 01:56:07:000

Shares of AnaptysBio ( ANAB ) rose by as much as 350% after my initial article prior to pulling back significantly. The stock was also one of the original selections in the ROTY 10 stock model account last year- while my plan had been to hold through phase 2a data in moderate to severe atopi… read more...

Reader Inquiry: AnaptysBio, Is It Time For Round 2 With This Former ROTY Winner?

via: SeekingAlpha at 2018-05-28 01:56:07:000

Shares of AnaptysBio ( ANAB ) rose by as much as 350% after my initial article prior to pulling back significantly. The stock was also one of the original selections in the ROTY 10 stock model account last year- while my plan had been to hold through phase 2a data in moderate to severe atopi… read more...

Reader Inquiry: AnaptysBio, Is It Time For Round 2 With This Former ROTY Winner?

via: SeekingAlpha at 2018-05-28 01:56:07:000

Shares of AnaptysBio ( ANAB ) rose by as much as 350% after my initial article prior to pulling back significantly. The stock was also one of the original selections in the ROTY 10 stock model account last year- while my plan had been to hold through phase 2a data in moderate to severe atopi… read more...

Reader Inquiry: AnaptysBio, Is It Time For Round 2 With This Former ROTY Winner?

via: SeekingAlpha at 2018-05-28 01:56:07:000

Shares of AnaptysBio ( ANAB ) rose by as much as 350% after my initial article prior to pulling back significantly. The stock was also one of the original selections in the ROTY 10 stock model account last year- while my plan had been to hold through phase 2a data in moderate to severe atopi… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-05-18 16:37:17:000

Noteworthy events during the week of May 20 - 26 for healthcare investors: More news on: uniQure N.V., Roche Holding Ltd ADR, BioMarin Pharmaceutical Inc., Healthcare stocks news, , Read more … read more...

Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite

via: SeekingAlpha at 2018-05-09 05:37:44:000

Biotechs are among the most risky of IPOs due to the binary nature of the success or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018, biotechs are increasingly going publ… read more...

Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite

via: SeekingAlpha at 2018-05-09 05:37:44:000

Biotechs are among the most risky of IPOs due to the binary nature of the success or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018, biotechs are increasingly going publ… read more...

Midday Gainers / Losers (4/5/2018)

via: SeekingAlpha at 2018-04-05 12:43:55:000

Gainers: LFIN +81% . NETE +26% . NVCN +26% . I +18% . VERI +18% . VTNR +12% . SNOA +14% . FTFT +15% . PLSE +14% . LEDS +13% . More news on: LongFin Corp, Net Element International, Inc., Neovasc Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (4/5/2018)

via: SeekingAlpha at 2018-04-05 12:43:55:000

Gainers: LFIN +81% . NETE +26% . NVCN +26% . I +18% . VERI +18% . VTNR +12% . SNOA +14% . FTFT +15% . PLSE +14% . LEDS +13% . More news on: LongFin Corp, Net Element International, Inc., Neovasc Inc., Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-04-04 08:26:59:000

Dexcom (NASDAQ: DXCM ) initiated with a Sell rating and $57 (24% downside risk) price target at Goldman Sachs. Initiated with Neutral rating at Guggenheim. Shares down 5% premarket. More news on: DexCom, Inc., NuVasive, Inc., Nevro, Healthcare stocks news, Stocks on the move, ,… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-04-04 08:26:59:000

Dexcom (NASDAQ: DXCM ) initiated with a Sell rating and $57 (24% downside risk) price target at Goldman Sachs. Initiated with Neutral rating at Guggenheim. Shares down 5% premarket. More news on: DexCom, Inc., NuVasive, Inc., Nevro, Healthcare stocks news, Stocks on the move, ,… read more...

Aimmune Still Leads In The Peanut Allergy Race

via: SeekingAlpha at 2018-04-02 11:49:58:000

One of the main recent stumbling blocks to upward movement in Aimmunes (AIMT) stock has been concern coming from a perceived existential threat to Aimmunes prospects from AnaptysBios (ANAB) monoclonal antibody approach to treating peanut allergy. Since the release of Ai… read more...

Aimmune Still Leads In The Peanut Allergy Race

via: SeekingAlpha at 2018-04-02 11:49:58:000

One of the main recent stumbling blocks to upward movement in Aimmunes (AIMT) stock has been concern coming from a perceived existential threat to Aimmunes prospects from AnaptysBios (ANAB) monoclonal antibody approach to treating peanut allergy. Since the release of Ai… read more...

Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data

via: SeekingAlpha at 2018-03-28 08:00:00:000

Analysis focus: Esperion Esperion Therapeutics (ESPR) shares have moved up sharply after the company announced top-line results from a phase 2 study ( 1002-039 ) evaluating the LDL-C lowering efficacy and safety of bempedoic acid 180 mg added-on to stable background therapy of a proprotein… read more...

Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data

via: SeekingAlpha at 2018-03-28 08:00:00:000

Analysis focus: Esperion Esperion Therapeutics (ESPR) shares have moved up sharply after the company announced top-line results from a phase 2 study ( 1002-039 ) evaluating the LDL-C lowering efficacy and safety of bempedoic acid 180 mg added-on to stable background therapy of a proprotein… read more...

AnaptysBio (ANAB) ANB020 Phase 2a Peanut Allergy Data - Slideshow

via: SeekingAlpha at 2018-03-27 15:30:00:000

The following slide deck was published by AnaptysBio in conjunction with this Read more … read more...

AnaptysBio (ANAB) ANB020 Phase 2a Peanut Allergy Data - Slideshow

via: SeekingAlpha at 2018-03-27 15:30:00:000

The following slide deck was published by AnaptysBio in conjunction with this Read more … read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: March 26, 2018

via: SeekingAlpha at 2018-03-27 05:49:26:000

The U.S. equity indexes rebounded today from key 200-day moving average support level after trade negotiations between the U.S. and China were reported. The buying accelerated later in the day indicating institutional interest (advancers: decliners= 68%: 23%). While it is unclear if we have se… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: March 26, 2018

via: SeekingAlpha at 2018-03-27 05:49:26:000

The U.S. equity indexes rebounded today from key 200-day moving average support level after trade negotiations between the U.S. and China were reported. The buying accelerated later in the day indicating institutional interest (advancers: decliners= 68%: 23%). While it is unclear if we have se… read more...

After Hours Gainers / Losers (3/26/2018)

via: SeekingAlpha at 2018-03-26 17:36:41:000

Top gainers: ANAB +7.5% . RHT +4.9% . BHVN +4.5% . QTNT +2.2% . PTGX +2.1% . More news on: AnaptysBio, Red Hat, Inc., Biohaven Pharmaceutical Holding Company Ltd., Stocks on the move, , Read more … read more...

After Hours Gainers / Losers (3/26/2018)

via: SeekingAlpha at 2018-03-26 17:36:41:000

Top gainers: ANAB +7.5% . RHT +4.9% . BHVN +4.5% . QTNT +2.2% . PTGX +2.1% . More news on: AnaptysBio, Red Hat, Inc., Biohaven Pharmaceutical Holding Company Ltd., Stocks on the move, , Read more … read more...

After-hours buzz: RHT, ANAB & more

via: CNBC at 2018-03-26 17:34:00:000

No summary available. read more...

After-hours buzz: RHT, ANAB & more

via: CNBC at 2018-03-26 17:34:00:000

No summary available. read more...

AnaptysBio's lead candidate shows positive effect in mid-stage peanut allergy study; shares ahead 7% after hours

via: SeekingAlpha at 2018-03-26 16:22:08:000

AnaptysBio (NASDAQ: ANAB ) is up 7% after hours on the heels of its announcement of positive preliminary results from a Phase 2a proof-of-concept clinical trial assessing lead drug ANB020 in adult patients with peanut allergy. More news on: AnaptysBio, Healthcare stocks news,… read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Key healthcare events next week (continued)

via: SeekingAlpha at 2018-02-09 12:37:01:000

Additional presenters at Leerink's Global Healthcare Conference in New York, February 14 - 15: More news on: Epizyme, Intra-Cellular Therapies Inc., Tocagen Inc, Healthcare stocks news, Read more … read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

My List Of The Best Early Stage Biotechs For 2018

via: SeekingAlpha at 2018-01-19 08:31:08:000

As each year goes by, I encounter "interesting" biotech companies and upon investigation, some of them make my buy list. Since I have a technical background, my attention focuses on their science, but just as important are competitive technologies, the market and the management team. Once a ye… read more...

When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018

via: SeekingAlpha at 2018-01-10 09:15:19:000

Market Pulse The year 2017 will be remembered as the year when the Bulls Growled and the Bears Mooed. A year when stock market volatility for the first time ever subsided to a level below that of bonds. A year when the market refused to relent to the historical valuation templates and hand… read more...

Stocks to watch next week

via: SeekingAlpha at 2018-01-06 09:10:16:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. More news on: Apple Inc., Amazon.com, Inc., Intel Corporation, Tech stocks news, … read more...

Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year

via: SeekingAlpha at 2017-12-20 10:00:00:000

An 11-year Seeking Alpha member, author Jonathan Faison focuses on discovering under-the-radar stocks and alpha-generating ideas for his readers. Operating primarily in the biotech sector, his specialty is looking specifically for opportunities to achieve high percentage gains within a year's … read more...

Your Daily Pharma Scoop: Valeant Still Risky, Onconova Signs Agreement, Array Biopharma Announces Collaboration

via: SeekingAlpha at 2017-12-20 05:46:56:000

Content Analysis of coverage: VRX Stocks in the news: ONTX, RGNX, ARRY Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Trade Idea for the Day (for TPT subscribers only) Subscriber Questions & Ans… read more...

Biotech Bonanza: Biotech Stocks To Keep Shining In 2018

via: SeekingAlpha at 2017-12-19 11:58:07:000

Biotechs have had a good year so far. Not a blistering rise, but nonetheless a steady rise. Of course, one expects even stronger performance on a relative basis from a higher-risk sector, particularly when the overall market continues to record all-time highs. Perhaps such out-performance is r… read more...

Nasdaq Biotech Index: 54 to be added, 15 removed

via: SeekingAlpha at 2017-12-11 07:45:08:000

Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...

Aimmune Therapeutics: Upside Into Q1 Data And Beyond

via: SeekingAlpha at 2017-12-07 00:55:18:000

Shares of Aimmune Therapeutics (AIMT) have risen by 75% since my late February article, where I called the stock a "solid Runner of the Year candidate." AIMT data by YCharts Keys to the original bullish thesis included the following: I was optimistic on oral biologic drug candidate… read more...

Medical Stocks: Investing For 2018

via: SeekingAlpha at 2017-12-01 08:40:00:000

2017 has turned out to be a good year for medical stocks, with strong gains in biopharmaceuticals, medical devices, diagnostics and HMOs. This can be attributed to a strong overall stock market, a quieting of concerns regarding drug pricing, an unchanged ACA and an underlying 6% growth rate … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX